Schizophrenia Clinical Trials in San Francisco
View 15 new treatments for Schizophrenia in San Francisco, CA, and nearby areas, such as Antioch, Berkeley, Concord, Daly City, Oakland, Richmond and Vallejo. Every day, Power helps hundreds of schiz patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
RL-007 for Cognitive Impairment in Schizophrenia
Recognify Life Sciences Clinic, Walnut Creek + 2 more
This trial is testing a new drug, RL-007, to see if it can help people with schizophrenia think and remember better. The study will compare different doses of the drug and check for any side effects. Participants will take the drug for several weeks and complete memory and thinking tests before and after the treatment.Show More
Verified
Recruiting
Phase 2
Est. 3 - 6 Weeks
Gary Walker, PhD
Study Director
KarXT for Schizophrenia
Karuna Clinic, Lafayette + 1 more
This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Ronald Marcus, MD
Study Director
Long-term Safety of Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Stanford + 1 more
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
KarXT for Schizophrenia
Karuna Clinic, Stanford + 4 more
This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Bristol-Myers Squibb
Study Director
Valbenazine for Schizophrenia
Neurocrine Clinic, San Jose + 1 more
This trial is testing whether adding the medication valbenazine can help people with schizophrenia who haven't improved enough with regular antipsychotic drugs. Valbenazine aims to balance brain chemicals to reduce symptoms.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Clinical Development Lead
Study Director
Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Lafayette + 1 more
This trial is testing a new medicine called iclepertin to see if it can help adults with schizophrenia improve their learning and memory. Participants will take either the medicine or a non-active substance while continuing their regular medication. Doctors will regularly check their mental abilities and overall health over several months.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Valbenazine for Schizophrenia
Neurocrine Clinic, Stanford + 2 more
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Clinical Development Lead
Study Director
OLZ/SAM for Schizophrenia
Alkermes Clinic, Stanford + 1 more
This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
David McDonnell, MD
Study Director
OLZ/SAM vs. Olanzapine for Schizophrenia or Bipolar Disorder
Alkermes Clinic, Stanford + 1 more
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
David McDonnell, MD
Study Director
Emraclidine for Schizophrenia
Cerevel Clinic, Lafayette + 1 more
This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.
Recruiting
No Placebo Trial
Phase 2
Est. 5 - 8 Weeks
Erica Koenig, PhD
Study Director
Page 1 of 2
Frequently Asked Questions
Explore related conditions